Treatment of γ-Aminobutyric AcidBReceptor–Antibody Autoimmune Encephalitis With Oral Corticosteroids | Epilepsy and Seizures | JAMA Neurology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.39.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
Aug 2012

Treatment of γ-Aminobutyric AcidBReceptor–Antibody Autoimmune Encephalitis With Oral Corticosteroids

Author Affiliations

Author Affiliations: Department of Neurology, University of California, Davis Medical Center, Sacramento (Drs Goldenholz, Bateman, Apperson, Oskarsson, Akhtar, and Wheelock); and Department of Neurology, University of Michigan, Ann Arbor (Dr Wong).

Arch Neurol. 2012;69(8):1061-1063. doi:10.1001/archneurol.2012.197
Abstract

Background Autoimmune encephalitis is increasingly identified as a cause of nonviral, idiopathic encephalitis. Present treatment algorithms recommend costly immune-modulating treatments and do not identify a role for oral corticosteroids.

Objective To present a patient with γ-aminobutyric acidB receptor–antibody encephalitis before and after treatment with oral corticosteroids.

Design Case report.

Setting The inpatient course as well as outpatient follow-up is discussed.

Patient A 43-year-old man with initial presentation of seizures and altered mental status.

Intervention Our patient was treated with an extended course of oral corticosteroids as an outpatient.

Results After treatment with oral corticosteroids, our patient had steady clinical improvement, achieved seizure freedom, and experienced improved mental status to within normal limits.

Conclusions This case supports the use of low-cost oral corticosteroids in treating patients with γ-aminobutyric acidB receptor–antibody encephalitis.

×